Getting to stage 3 is a huge accomplishment. Here is an average for all studies on the success at passing stages :
passing Phase 1 : 63%
passing Phase 2 : 31%
passing Phase 3 : 58%
Approval : 85%
So getting past phase 2 is the hardest thing. Downhill from there. And if we have got to stage 3 for one treatment, the likelyhood is greater for other similar treatments.
ref : https://www.bio.org/sites/default/f...6-2015 - BIO, Biomedtracker, Amplion 2016.pdf
- Forums
- ASX - By Stock
- QIN
- Take over, Call me craxy
Take over, Call me craxy, page-2
Featured News
Add QIN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online